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A Model-Predictive Hypnosis Control System
Under Total Intravenous Anesthesia
Yoshihito Sawaguchi*, Member, IEEE, Eiko Furutani, Gotaro Shirakami, Mituhiko Araki, Fellow, IEEE, and
Kazuhiko Fukuda
Abstract—In ambulatory surgery, anesthetic drugs must be
administered at a suitable rate to prevent adverse reactions
after discharge from the hospital. To realize more appropriate
anesthesia, we have developed a hypnosis control system, which
administers propofol as an anesthetic drug to regulate the bis-
pectral index (BIS), an electroencephalography (EEG)-derived
index reflecting the hypnosis of a patient. This system consists of
three functions: 1) a feedback controller using a model-predictive
control method, which can adequately accommodate the effects of
time delays; 2) a parameter estimation function of individual dif-
ferences; and 3) a risk control function for preventing undesirable
states such as drug overinfusion or intraoperative arousal. With
the approval of the ethics committee of our institute, 79 clinical
trials took place since July 2002. The results show that our system
can reduce the total amount of propofol infusion and maintain the
BIS more accurately than anesthesiologist’s manual adjustment.
Index Terms—Bispectral index (BIS), hypnosis control system,
model-predictive control, propofol.
I. INTRODUCTION
DURING general anesthesia, anesthetic agents must beadministered adequately to prevent intraoperative arousal
and postoperative adverse reactions. This demand is crucial in
ambulatory surgery because patients must remain in the hos-
pital overnight if the adverse reactions are severe. To satisfy the
demand, an intravenous anesthetic agent, propofol, is widely
used for ambulatory anesthesia because propofol possesses
favorable pharmacokinetic profiles [1] and shows reduced fre-
quency of postoperative adverse reactions such as postoperative
nausea and vomiting (PONV) [2]. The infusion rate of propofol
during general anesthesia must be adjusted carefully to realize
these merits. For that reason, numerous studies of automatic
administration of propofol have been done [3]–[13]. Among
them, target controlled infusion (TCI) system [3] is well known
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and now widely accepted. The TCI system administers propofol
to regulate the propofol concentration in plasma or at the effect
site of propofol close to a target level. It uses a pharmacokinetic
model of propofol as a dynamic model to estimate and thereby
regulate the concentration. Some researchers have advocated
that the TCI system has sufficient performance for clinical use
[4]. However, from the viewpoint of control engineering, the
TCI system works as an open-loop controller and does not have
tracking ability to a target. Consequently, anesthesiologists
should adjust the target concentration suitably to cope with
individual differences and noxious stimuli during surgery.
On the other hand, automatic infusion systems with feedback
mechanisms have been studied [5]–[13] to handle the individual
differences and the noxious stimuli adequately. They used an
index derived from spontaneous electroencephalography, the
bispectral index (BIS) [14], which is a satisfactory index of
hypnosis under propofol anesthesia [15], [16]. In such systems,
proportional–derivative (PD) or proportional–integral–deriva-
tive (PID) controllers [5]–[10], a model-based controller [11],
[12], or a nonlinear adaptive controller [13] were used. How-
ever, most of those studies did not take into account the delays
caused by the movement of propofol in an intravenous line,
the distribution of propofol in blood vessels, and the signal
processing time within the BIS monitor [17]. Struys et al. [12]
took the delays into account in estimation of patient-specific
parameters, but that system required much time, and the control
strategy was unable to cope adequately with the delays. Bailey
and Haddad [13] pointed out the need for consideration of the
delays, because an undershoot of the BIS at the induction of
anesthesia occurred in their nonlinear adaptive control system.
We have developed a hypnosis control system using the BIS
as the index of hypnosis and propofol as the intravenous anes-
thetic agent. The system uses a model-predictive controller [18],
which can rigorously take the delays into account. Moreover, it
has a function of rapid estimation of individual pharmacody-
namic parameters from the BIS response during the induction
of anesthesia. With the approval of the Ethics Committee of
the Kyoto University Graduate School and Faculty of Medicine,
Kyoto, Japan, we applied the system to various kinds of ambu-
latory surgery at Kyoto University Hospital, Kyoto, Japan, and
confirmed its accuracy in hypnosis control and effects of drug
reduction. While a brief explanation of this system and main re-
sults were presented in [19] and [20], this paper describes the
details of a model of BIS response to propofol infusion, the pa-
rameter estimation function, the control law, and the risk control
function. Furthermore, the results of clinical trials are compared
with those of other hypnosis control systems [5], [8]–[10], [12]
and anesthesiologist’s manual adjustment.
0018-9294/$25.00 © 2008 IEEE
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TABLE I
PHARMACOKINETIC PARAMETER VALUES PUBLISHED BY SCHÜTTLER AND IHMSEN [21]
This paper is organized as follows. Section II is devoted to de-
scription of the model of the BIS response to propofol infusion.
Individual differences in model parameters are also considered.
In Section III, we explain a function for estimation of the indi-
vidual differences, strategy and design of model-predictive con-
troller, and a risk control function of the system. In Section IV,
our clinical system and the results of the clinical trials are pre-
sented. Evaluation of the controller performance and discussion
are made in Section V.
II. MODEL OF HYPNOSIS CHANGE TO DRUG INFUSION
A mathematical model of the process is necessary to design
an appropriate controller for a specific process. The accuracy
of the model strongly affects the performance of control sys-
tems, especially when a model-based controller is used. In this
section, we introduce a model of the BIS response to propofol
infusion. The model is a series connection of three elements: a
pharmacokinetic model, a time delay, and a pharmacodynamic
model. In Sections II-A and II-B, detailed descriptions of re-
spective elements are presented.
A. Pharmacokinetic Model
Pharmacokinetic models describe the dynamics of drug
concentration in human body. We construct a pharmacokinetic
model based on the population pharmacokinetic model given
through a large-scale multicenter study by Schüttler and Ihmsen
[21] because this model incorporates the patient’s age and body
weight (BW) and seems to be sufficiently reliable. However,
the Schüttler–Ihmsen model does not include the effect site
[22] that relates directly to the BIS. Furthermore, the model
parameters for continuous infusion of the Schüttler–Ihmsen
model differ from those for a bolus. Considering these factors,
we propose a unified model that can accommodate both bolus
and continuous infusion and attach the effect site compartment
to the unified model.
The original version of the Schüttler–Ihmsen model is given
as (1), shown at the bottom of the page. Here, is the concen-
tration of propofol in compartment ; compartments 1, 2, and
3 correspond, respectively, to the central, shallow peripheral,
and deep peripheral compartment. In addition, is the infusion
rate of propofol, and and are the clearance and volume of
compartment , respectively, given as functions of the patient’s
age and BW, as in Table I. The superscripts and of the
parameters in Table I, respectively, designate administration by
bolus and continuous infusion.
Based on (1), we constructed a unified model under the fol-
lowing assumptions.
• The parameter values of the unified model to continuous
infusion, except for those of the effect site, are given by
the parameter values for continuous infusion in Table I,
because anesthesia is usually maintained by continuous
infusion.
• In the bolus case, infused propofol moves directly to the
shallow peripheral compartment and to the central com-
partment, as shown in Fig. 1.
Physiologically, a bolus of propofol reduces hepatic
blood flow [23], which decreases the clearance of the
central compartment. Consequently, the bolused propofol
remains in the patient’s body for a longer time than in
continuous-infusion cases. Although this phenomenon
might be considered by a nonlinear clearance, such non-
linearity increases the model complexity. Furthermore,
the exact form of the nonlinearity has never been shown.
For those reasons, we introduce a linear model that imi-
tates this phenomenon by assuming that a fraction of the
bolused propofol accumulates in the shallow peripheral
compartment, and fades after the transition to the central
compartment.
• The volume of the effect site compartment is one hun-
dredth of the central compartment. Namely, is set to
.
Many studies have subsumed that this volume is negligible.
However, that consideration relies on the assumption that
a drug is metabolized or eliminated at the effect site. That
assumption seems to be irrelevant for hypnotic agents. Fur-
thermore, the assumption changes the relative degree of a
(1)
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Fig. 1. Three-compartment pharmacokinetic model with the effect site and a direct route to a shallow peripheral compartment for a bolus.
transfer function of the process. For those reasons, we did
not neglect the volume of the effect site compartment, and
regarded it to one hundredth of the central compartment.
The constructed pharmacokinetic model is given as
(2), shown at the bottom of the page, with
, where is the propofol
concentration in the effect site compartment, is the
bolus rate, and is the continuous infusion rate. Con-
stants and are input coefficients for the bolus, and they
are given by solving the minimization problem of the quadratic
error between after a single bolus (an impulse input) of
the Schüttler–Ihmsen model and that of (2). The clearance of
the effect site compartment was determined from preliminary
data collected from 47 patients [male/female 16/31, age 48
18 years (mean SD), BW 57 11 kg] under various kinds
of ambulatory surgery. In these measurements, propofol was
administered at the rate of 120 mg/kg/h for the first 1 min,
then at the rate of 10 mg/kg/h for the subsequent 2 or 3 min.
Thereafter, the rate was adjusted to maintain the BIS within the
range of 40–60 until surgery was completed. The values of the
BIS and infusion rate were obtained in every 1 s. Using these
measurements, was set to 0.12 L/min to make the median
peak time [24] of the effect site concentration calculated using
(2) coincide with the time between the beginning and the peak
of the averaged BIS decrease among the patients.
In the following, we treat the infusion whose rate is greater
than , the threshold rate of the continuous infusion, as a





The threshold rate is set to 20 mg/kg/h, which is twice the
upper bound of the adequate infusion rate recommended by the
supplier (AstraZeneca, Osaka, Japan), because we consider that,
in most situations, the rate is sufficiently large for mainte-
nance of anesthesia. In all the collected data, the continuous in-
fusion rate of propofol was less than .
Fig. 2 shows responses of to a bolus and continuous
infusion for the Schüttler–Ihmsen model and the constructed
unified model for a 40-year-old patient whose BW is 60 kg.
These figures show that the unified model provides adequate
responses both to the bolus and continuous infusion over the
whole time domain. Similar results were obtained for patients
of all ages and BWs.
B. Time Delays and the Pharmacodynamic Model
In this section, we present a detailed description of delays and
a pharmacodynamic model, and estimate their parameter values
from preliminary measurements. Furthermore, the necessity for
consideration of individual differences is described.
The response of the BIS to propofol infusion includes consid-
erable time delays, which are caused by movement of propofol
from a three-way stopcock to the patient’s body in an intra-
venous fluid line, distribution of propofol in blood vessels (the
central compartment), and calculation time of the BIS in the BIS
monitor (approximately 15–60 s [17]).
The process is a single-input–single-output system. There-
fore, we consider a single-output delay whose length is the
sum of the delays described previously. That is, the current BIS




A pharmacodynamic model describes the relationship be-
tween the propofol concentration in the effect site compartment
(2)
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Fig. 2. Plasma propofol concentration of the conventional pharmacokinetic model published by Schüttler and Ihmsen [21] and the proposed model. (a) Plasma
propfol concentration to 1-mg/kg bolus. (b) Plasma propofol concentration to 10-mg/kg/h continuous infusion.
and the BIS. We use the sigmoidal model [25] because
it is widely accepted in pharmacodynamic studies of propofol
[26], [27]. This model is given as
BIS (8)
where BIS is the current BIS, is the BIS on awak-
ening, is the maximum-effect intensity, is the propofol
concentration corresponding to the , and is the Hill
coefficient.
Next, we estimate the actual values of the delay length and
pharmacodynamic parameters from the 47 data sets described
in Section II-A. These estimates are used for validation of a
closed-loop controller.
To begin with, the delay length is estimated for each
measurement. First, propofol concentration in the effect-site
compartment is calculated from the propofol infusion rate
and (2). Then, the estimate of the delay length is
determined through trial and error so that the relation between
and BIS during the induction (the first 120 s after the
start of infusion) approaches the relation during the awakening
period (time period after the stop of infusion), as presented in
Fig. 3(a) and (b).
Under the assumption that , which means the
BIS tends to when propofol concentration in the effect site
becomes infinite, other parameters are estimated as follows.
is set to the maximum BIS value before the start of infusion. The
constants and are determined through exhaustive search




where , , and mean the induction, awakening, and main-
tenance period that are defined, respectively, as the period up to
120 s from the start of infusion, the period after the end of infu-
sion, and the period between induction and awakening periods.
Moreover, length represents the number of data points in .
In the preliminary 47 data sets, the estimates of , , ,
and are 68 34 s, 97.3 0.8, 3.90 1.05 g/mL and 1.81
0.67, respectively. The mean and standard deviation of the mea-
sure for each measurement are 95.7 and 52.9, respectively.
The measure with fixed parameter values is calculated to con-
sider the effect of individual differences. Substituting the mean
values of the estimates into , , , and , the mean and
standard deviation of measure are 266.2 and 151.9, respec-
tively. The mean is significantly larger than that with the indi-
vidualized parameters. Therefore, we should consider the indi-
vidual differences of these parameters.
Additionally, we introduce a linear pharmacodynamic model
as
BIS BIS (10)
and compare the model fitness for the nonlinear and linear
model. The parameters and BIS are identified individually
using least-squares method under the same measure of model
fitness. The identified values of and BIS are, respectively,
11.5 3.9 and 94.7 11.7. The mean and standard deviation
of the measure are 112.6 and 57.3, respectively. The mean is
larger than that with the nonlinear model with individualized
parameters. Therefore, the nonlinear pharmacodynamic model
(8) is more adequate than the linear one. In the following,
we consider the nonlinear pharmacodynamic model using
individualized parameters.
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Fig. 3. BIS values versus effect site concentrations. (a) When the delay is not considered (L^ = 0), the relation between BIS and the effect site concentration
shows a hysteresis loop. (b) When the delay is considered adequately (L^ = 60 s), the relation between BIS and the effect site concentration during the induction
period approaches the relation during the awakening period.
III. HYPNOSIS CONTROL SYSTEM
In this section, our hypnosis control system is explained in de-
tail. The main components of the control system are an estima-
tion function of individual parameters during induction of anes-
thesia, a model-predictive controller, and a risk control function
for prevention of undesired states. In Sections III-A–III-C, the
detailed descriptions of these components are given.
A. Parameter Estimation During Induction
As presented in Section II-B, the individual differences in
the pharmacodynamic parameters and the delay length are
quite large. The differences might degrade the hypnosis control
performance if they are not treated adequately. Therefore, we
developed a parameter estimation function that estimates the
pharmacodynamic parameters and the delay length from the
Authorized licensed use limited to: Kyoto University. Downloaded on June 29, 2009 at 01:13 from IEEE Xplore.  Restrictions apply.
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TABLE II
PERMISSIBLE RANGES AND DEFAULT VALUES FOR PARAMETER ESTIMATION
response of the BIS to propofol infusion during induction of
anesthesia.
For induction of propofol anesthesia, propofol is usually
administered as sequential bolus and continuous infusion
[28] to anesthetize patients quickly. According to the widely
accepted procedure for propofol-induced anesthesia, our hyp-
nosis control system administers propofol at the respective
rates of 120 mg/kg/h and 10 mg/kg/h for the first 1 min and the
subsequent 2 or 3 min. In the end of this induction period, the
individual delay length and pharmacodynamic parameters
, , , and are estimated from the response of the
BIS and the calculated effect site concentration. Immediately
after the parameter estimation is completed, parameters of the
controller are adjusted using the estimation result, and feedback
control starts.
In the following, we explain important details of the param-
eter estimation method. First, and are determined as
the maximum value of the BIS before the bolus of propofol.
Next, the delay length is determined using an estimation
equation
s (11)
where is the time when BIS reaches . Equation
(11) is derived from least-squares fitting of and the delay ,
estimated using trial and error, in the preliminary 47 data sets,
because they are strongly correlated: the correlation coefficient
is 0.956. The standard deviation of the estimation error




using measurements obtained during the BIS descending period
from the start of infusion up to s. The above equa-
tion is derived from (8), as in the Appendix. Using this method,
the delay length and pharmacodynamic parameters of each are
estimated during the induction period.
This parameter estimation works well for almost all cases.
However, the estimator must respond to device failures or
severely abnormal measurements. If any obtained parameter
value is out of the corresponding range shown in Table II, the
parameter is set at the upper or lower bound of the range. If
the measured data are unreliable, in other words, if the signal
quality of electroencephalogram is fatally low or the BIS is
higher than during the 180 s after the start of the
bolus, the parameters are set to the default values shown in
Table II. The upper and lower bounds and default values are
determined to guarantee the robust stability of control system
under possible parameter differences estimated from the pre-
liminary measurements.
B. Model-Predictive Controller
In this section, we introduce a model-predictive controller
[18] for controlling the hypnosis level of patients during general
anesthesia. As described in Section II-B, the model of the BIS
response to propofol infusion includes a delay. Furthermore, the
infusion rate must be nonnegative. We designed a model-predic-
tive controller to handle the delay and input constraint appro-
priately. In the following, we explain the salient details of the
model-predictive controller that we use in our hypnosis control
system.
1) Linearization of Model: The model of the BIS response
to propofol infusion includes the nonlinear pharmacodynamic
model. The model is linearized by an inverse of the pharmaco-
dynamic model to simplify computation in the model-predictive
controller.
We consider the controlled process as the linearized system
obtained by adding the inverse of the pharmacodynamic model
to the output side of the process. That is, we regard the effect




In a similar way, the target value for the model-predictive con-




where BIS is the target value of the BIS. Although the
nominal values of parameters used in (13) and (14) might differ
from the actual value of the process, the BIS coincides with its
target value when the controlled variable reaches
its target value because the pharmacodynamic model and
its inverse are one-to-one mappings.
2) Control Law: The control law of our model-predictive
controller is shown here. First, we introduce notation and
assumptions. We, respectively, describe the starting time of
propofol infusion and the present time as and ,
where is the sampling period of the controller. We assume
that the initial state is zero, for , because
no propofol exists in the patient’s body before the start of
propofol infusion. Furthermore, we assume that the bolus of
propofol will not be administered after the present time and
that the infusion rate of propofol will be changed only at every
sampling instant. That is, the future inputs are assumed to be
(15)
(16)
where for is the infusion rate of propofol
during the future period .
Under these assumptions, the future output is predicted by the
model. From the initial condition and the past input
for , the future output of the
nominal model for is predicted as a function of future
inputs , using (2) and (7). Additionally, a constant
disturbance
(17)
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is introduced to suppress the output disturbance and the error
resulting from model mismatches [18]. Consequently, the pre-
dicted output is given as
(18)
Next, we introduce the reference trajectory that the predicted
output should track as closely as possible. We use the reference
trajectory for the effect-site concentration to avoid aggressive
control action. Using the target value and the predicted
output at time point , the reference trajectory
for is set as
(19)
where is a time constant of the reference trajectory.
Then, future input values are calculated as the





where is the length of a control horizon, is the length
of a prediction horizon, and is a weighting coefficient for the
input to the output error.
Finally, the controller applies the first element of the fu-
ture inputs, which were obtained by solving the optimization
problem (20), to the controlled process, and repeats this proce-
dure at each sampling time.
3) Controller Design: In this section, we give specifica-
tions of the control system and design the model-predictive
controller. The hypnosis level of the patient should approach
quickly to the target value and then be maintained around the
target. Furthermore, the control system must be robustly stable
for individual differences among patients, although the effect
of the differences might be suppressed partly by the parameter
estimation function. Taking these requirements into account,
the specifications of the hypnosis control system are given for
patients whose age, BW, and delay length are in the ranges of
18–80 years, 40– 100 kg, and 30–150 s, respectively. First,
the 5% settling time of the model-predictive control system
should be less than 15 min to provide clinically acceptable
responses. Second, the control system should be stable for
and , where and are
actual and nominal delay lengths and is the relative gain
between the actual and nominal processes. These ranges are
given by the three sigma limits of relative mismatch of delay
estimate in Section III-A and those of linear gain estimated in
Section II-B, respectively.
To satisfy those specifications for every patient model in the
targeted characteristic group, the controller parameters , ,
, , and are configured. The sampling period of the
controller is set to 10 s under a mechanical restriction of a sy-
ringe pump. The length of the control horizon is set to one
because the control system must have sufficient robustness. The
time constant of the reference trajectory is set to 245 s so
that the settling time of the reference trajectory meets the spec-
ification of settling time. The length of the prediction horizon
and the weighting coefficient are set to and
( g/mL) /(mg/kg/h) by trial and error to provide a
sufficient robust stability margin of the closed-loop system.
Typical nominal responses are shown in Fig. 4, which shows
the nominal step response of the closed-loop system and the
nominal closed-loop response after the sequential bolus and
continuous infusion for a 40-year-old, 60-kg patient with mean
parameter values described in Section II-B. We can confirm that
adequate control is achieved and that the settling time is less
than 15 min. A typical result of robust stability analysis for the
same patient model is shown in Fig. 5. This figure is obtained
from the Nyquist stability condition with the assumption that
the modeling errors exist only in the linear gain and the delay
length [29]. We can confirm that the robust stability region is
sufficiently large to satisfy the specified requirement.
We repeated simulations and analysis for models of patients
without or with model mismatches on pharmacokinetic and
pharmacodynamic parameters and delay length. The mis-
matches were given as normally distributed random values,
whose mean and standard derivation were the nominal values
and one fifth of the nominal values for pharmacokinetic param-
eters, and the mean and standard derivation of the estimates in
the preliminary 47 data sets for pharmacodynamic parameters
and delay length, respectively. Under these model mismatches,
we confirmed that our hypnosis control system satisfies the
given specifications.
C. Risk Control Function
In the usual mode, the infusion rate of propofol is adjusted
by the model-predictive controller to maintain the BIS around
the target value. However, unmodeled surgical disturbances and
sensitive autonomic nervous system might cause undesirable
states, such as intraoperative arousal, hypotension, and brady-
cardia. To prevent these undesirable states as well as overinfu-
sion of propofol, we implement a rule-based risk control func-
tion that imitates countermeasures taken by anesthesiologists
for such states because the model-predictive controller cannot
respond quickly to such unmodeled factors. In the following,
we explain each risk-avoiding action.
1) Prevention of Propofol Overinfusion: To avoid adverse
reactions of propofol overinfusion, such as a delay of arousal or
PONV, the upper bound of the infusion rate is set to 20 mg/kg/h,
except the bolus for a countermeasure to intraoperative arousal.
Moreover, the bolus dose for the countermeasure to intraopera-
tive arousal is limited to less than 1 mg/kg, as explained
in the following.
2) Countermeasure to Intraoperative Arousal: The system
administers a bolus of propofol to prevent intraoperative arousal
when the BIS rises abnormally. The dose and rate of the bolus
Authorized licensed use limited to: Kyoto University. Downloaded on June 29, 2009 at 01:13 from IEEE Xplore.  Restrictions apply.
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Fig. 4. Simulation results of the closed-loop system with a model of patient whose age, BW, and delay length are 40 years, 60 kg, and 70 s. In each figure, the
upper panel shows propofol concentrations at the effect site, and the lower panel shows the infusion rate of the propofol (solid line), and the BIS (dashed line). The
setpoints of the concentration and the BIS are set, respectively, to 3.6 g/mL and 50. (a) Nominal step response. (b) Nominal response after the sequential bolus
and continuous infusion.
are determined based on the BIS rise BIS BIS
BIS , by the following procedure.
• When the bolus at the induction is completed, is set
to 2 mg/kg. Here, is a fictitious dosage, which corre-
sponds to the effect of past boluses.
• During continuous infusion, is decreased exponen-
tially with a time constant of 195 s.
• When BIS is greater than 15, the system sets a limit
dose of the following bolus to , and
starts a bolus at the rate of 30 mg/kg/h.
• During the bolus, the bolus rate is increased to 60, 90, and
120 mg/kg/h if the respective BIS are greater than 25,
35, and 45. On the other hand, the rate is decreased to 90,
60, and 30 mg/kg/h if BIS falls under 40, 30, and 20,
respectively. If BIS falls below 10 or the bolus dose
reaches , the bolus is terminated, and the bolus dose is
added to .
3) Management for Hypotension and Bradycardia: To cope
with adverse reactions of propofol to the patient’s cardiovas-
cular system, the system continuously monitors the noninvasive
systolic pressure and pulse rate. When these values respectively
fall below 70 mmHg and 40 b/min, the system sounds an alarm
and decreases the propofol infusion rate according to a predicted
awakening time. The predicted awakening time is calculated
from (2) and (7) as the time for to reach , which is the
effect site propofol concentration corresponding to BIS ,
under the assumption that . The propofol
infusion rate is set to zero if the predicted awakening time is
Authorized licensed use limited to: Kyoto University. Downloaded on June 29, 2009 at 01:13 from IEEE Xplore.  Restrictions apply.
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Fig. 5. Stability region of the closed-loop system in the gain–time-delay plane
for a model of patient whose respective age, BW, and delay length are 40 years,
60 kg, and 70 s. Solid lines mean the nominal values and dashed lines mean the
three sigma limits.
longer than 4 min. Otherwise, the propofol infusion rate is set to
a half of the calculated rate by the model-predictive controller.
4) Countermeasure to BIS Noise: The BIS is calculated from
the measured EEG. When an electric knife is used, a signal
quality of the EEG worsens because of electrical noise; some-
times the BIS output is suspended. Moreover, when the myo-
genic potential appears frequently on the EEG, the BIS output
is also suspended. During the suspension, the model-predictive
controller cannot obtain the measured output. Therefore, the
controller determines the propofol infusion rate assuming that




Implementation of the hypnosis control system is shown in
Fig. 6. This system measures the BIS, the noninvasive systolic
blood pressure, and the pulse rate. The BIS is measured using
a BIS monitor (A-2000; Aspect Medical Systems, Newton,
MA). The noninvasive systolic blood pressure and the pulse
rate are measured using a central monitoring system (Agilent
Technologies, Palo Alto, CA). The propofol is administered
using a syringe pump (Graseby 3500; Graseby Medical Ltd.,
Walford, U.K.) via an intravenous fluid line. An IBM-compat-
ible personal computer (PC) is used to calculate the infusion
rate of propofol. These instruments are connected via RS-232
serial connections, and driven by software written by one of
the authors (Y. Sawaguchi) in a commonly used computer
language (Microsoft Visual C++ Ver. 6; Microsoft Corporation,
Redmond, WA).
B. Clinical Protocols
After obtaining the approval of the Ethics Committee of the
Kyoto University Graduate School and Faculty of Medicine,
160 adult patients [American Society of Anesthesiologists
(ASA) physical status (PS) class I-II; age, 18–80 years; body
mass index (BMI), 15–36 kg m ] undergoing elective various
kinds of ambulatory surgery were included in this study. They
Fig. 6. Structure of our clinical trial system. The system comprises a BIS mon-
itor, a patient monitoring system, a syringe pump, and a laptop computer. These
devices are connected using RS-232 serial cables.
were assigned randomly to either group A (automatic control)
or M (manual adjustment) using the envelope method.
Before induction, all patients were instructed to close their
eyes. In group A, patients’ hypnosis was controlled by our
hypnosis control system, whereas patients in group M received
propofol administration whose infusion rate was adjusted man-
ually by one author (G. Shirakami) after 2-mg/kg initial bolus
and 10-mg/kg/h continuous infusion at an induction period. In
both group, the target value of the BIS was set to 50 because
the desired level of the BIS during surgery is 40–60 [15].
Supplemental IV fentanyl and vecuronium, local infiltration
anesthetics, and rectal diclofenac were administered for pain re-
lief and muscle relaxation during anesthesia. Boluses of fen-
tanyl (25 g each) were administered at the start of propofol
infusion, before and 30 min after skin incision, and before skin
closure. Vecuronium and rectal diclofenac were administered
after loss of consciousness. The initial dose of vecuronium was
0.06–0.12 mg/kg, depending on the estimated duration of anes-
thesia. Additional administration of vecuronium was done if
insufficient muscle relaxation was observed. Local infiltration
anesthetics were administered before the start and at the end of
the operation by surgeons. In all cases, anesthesia care was pro-
vided by one author (G. Shirakami).
After each surgery, propofol infusion was terminated by the
anesthesiologist. The recovery time from the stop of infusion to
tracheal extubation or laryngeal mask airway (LMA) removal
and the time required for the BIS to be above 80 after the stop
of infusion were recorded.
In all cases, the BIS and infusion rate of propofol were
recorded on a computer every second. Episodes of hypoten-
sion (systolic blood pressure 70 mmHg) and bradycardia
(pulse rate 40 b/min) were also recorded. Evaluation and
comparison of results were performed after all trials. Statistical
analyses were performed using Student’s -test. Differences of
were inferred to be statistically significant.
C. Results
In one case of automatic control, a misuse of the syringe
pump engendered device failure. Consequently, that case was
excluded from subsequent analyses.
Between the two groups, no statistically significant differ-
ences were found in patient characteristic data, type of surgery,
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TABLE III
PATIENT CHARACTERISTICS, PERFORMANCE INDICES, DRUG CONSUMPTION,
AND OCCURRENCE OF ABNORMAL STATE OF AUTOMATIC CONTROL
AND MANUAL ADJUSTMENT
duration of propofol infusion, or consumption of drugs aside
from propofol, as shown in Table III. In both groups, adequate
anesthesia was achieved in all cases.
The BIS and the infusion rate in typical cases of automatic
control and manual adjustment are shown, respectively, in
Fig. 7(a) and (b). Fig. 7(a) shows the BIS and infusion rate for a
46-year-old male who underwent oral surgery. In this case, the
parameter estimation was completed at 2.7 min after the start of
infusion. The infusion was terminated at 138.8 min. During the
control period, defined as the period between the completion of
the parameter estimation and the termination of infusion, the
averages of the BIS and of the propofol infusion rate were 49.2
and 5.8 mg/kg/h, respectively. The settling time, defined as the
time that the BIS is reached and is maintained within 40–60 for
5 min, was 10.0 min. The time in the target zone, defined by
the percentage of time when the BIS is within 40–60 during the
control period, was 90.8%. The recovery time until extubation
and the time required for the BIS to be above 80 after the stop
of infusion were, respectively, 6.9 and 3.0 min.
Fig. 7(b) also represents the BIS and infusion rate for a
57-year-old female patient who had oral surgery under manu-
ally adjusted propofol anesthesia which lasted 123.5 min. For
manually adjusted cases, we define the control period as the
period from 4 min after the start of propofol infusion to the stop
of infusion. The averages of the BIS and infusion rate during
the control period were 51.7 and 9.8 mg/kg/h. The settling time,
the time in target zone, and the recovery time to extubation and
to BIS 80 were, respectively, 22.8 min, 82.4%, 5.0 min, and
12.3 min.
The aggregated results of each group are shown in Fig. 8 and
Table III. Fig. 8 presents the average and standard deviation of
all time courses of the BIS and infusion rate before the stop of
infusion. The averaged BIS is clearly closer to the setpoint, and
the standard deviation of infusion rate is larger in our system.
This means that our system can make the BIS closer to the set-
point taking individual differences of propofol requirement into
account. In Table III, the mean values and standard deviations
of the averaged BIS during the control period, the averaged in-
fusion rate, the settling time, the time in target zone, and the re-
covery time to BIS 80 and tracheal extubation/LMA removal
of each group are shown. Between the two groups, the averaged
BIS, the averaged infusion rate, and the time in target zone differ
significantly. In group A, abnormal BIS rise and propofol bolus
occurred more frequently than in group M, whereas the fre-
quency of hypotension and bradycardia did not differ between
the two groups.
V. DISCUSSION
In this study, a model-predictive controller was developed
for closed-loop control of hypnosis using propofol. The system
is applied for ambulatory surgery because adverse reactions
of propofol overdose are severe problems, especially for such
situations. The proposed control framework combines the
following: 1) a new description of propofol pharmacokinetics
based on the result of Schüttler and Ihmsen [21], 2) a fast and
reliable estimation of individual pharmacodynamic parameters,
3) a model-predictive controller that can easily incorporate
information of a time delay and input constraints, and 4) a
risk control function as a countermeasure to undesirable states.
The model-predictive control strategy is a powerful method for
controlling the pharmacological model of propofol; it achieves
stable control in the presence of mismatches of time delay
and gain. In the clinical trials, the model-predictive hypnosis
control system can maintain patients’ hypnosis adequately.
Hereafter, we compare the results of clinical trials with those
of previous works [5], [8]–[10], [12] and anesthesiologist’s
manual adjustment.
A. Comparison With Other Closed-Loop Systems
In most previous works, median performance error (MDPE)
and median absolute performance error (MDAPE) were used to
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Fig. 7. Representative plots of both groups. In each figure, the upper and lower panels, respectively, show the BIS and infusion rate of propofol. (a) Typical result
of automatic control (group A). (b) Typical result of manual adjustment (group M).
indicate the performance of the controller [5], [8]–[10], [12].
The MDPE and MDAPE are measures of performance error





The MDPE is a median of the PE, and the MDAPE is a median
of the absolute values of the PE.
Table IV shows the MDPE and MDAPE of our system and
those of previous works [5], [8]–[10], [12]. Table IV shows that
the MDPE and the MDAPE of our system were not so good.
A main reason for this is probably a pain relief method. In pre-
vious closed-loop systems, patients received epidural anesthesia
[8] or higher dose opioids [5], [9], [10], [12] than in our trials.
For example, Absalom et al. [8] administered epidural anes-
thesia with 0.5% bupivacaine 10 mL and Liu et al. [10] and
Struys et al. [12], respectively, used remifentanil infusion at the
rates of about 0.22 g/kg/min and at least 0.25 g/kg/min. In
general, fluctuations of the BIS caused by painful stimulus de-
pend on the level of analgesia [30]. Epidural anesthesia can pro-
duce dense sensory blockage; consequently, perturbation of the
BIS during surgery can be suppressed. Intraoperative adminis-
tration of opioid similarly affects the perturbation of the BIS
[31]. However, epidural anesthesia requires a preparation time,
causes delay of postoperative recovery, and poses risks of failure
and accidental dural puncture. The high-dose administration of
opioids causes adverse reactions such as PONV [32], which
delays discharge from the hospital. Therefore, these analgesic
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Fig. 8. BIS and infusion rate from induction to discontinuation of infusion for automatic control and manual adjustment groups. Average values (solid line) are
presented with standard deviation values (dashed line). (a) Automatic control (group A). (b) Manual adjustment (group M).
methods are inappropriate for ambulatory surgery. On the other
hand, we used intermittent fentanyl infusion for analgesia: its
total amount was less than 100 g. For that reason, our MDAPE
was larger than others. For an appropriate comparison of the
MDAPE, similar analgesic regimens must be used.
The MDPE of our system is not good, perhaps because of the
use of the propofol bolus as a countermeasure to intraoperative
arousal. The bolus was stopped when the BIS fell under 60.
However, the BIS continues to decrease after the stop of the
bolus because of the time delay. Sometimes undershooting of
the BIS to the target value of 50 occurs because the bolus dose
is too large. To prevent an unnecessary BIS decrease, the effect
of the delay must be considered adequately and the bolus dose
TABLE IV
MDPE AND MDAPE OF OUR SYSTEM AND OTHER PUBLISHED
HYPNOSIS CONTROL SYSTEMS
should be determined based on the future BIS predicted by a
model with the consideration of disturbances.
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Another possible reason for the worse performance is the in-
accuracy of the model. We have utilized a custom-made phar-
macokinetic–pharmacodynamic (PK–PD) model. Although our
PK–PD model has worked well, the model is not necessarily
the best for prediction of the BIS response. This is because the
model always has mismatches, which include individual differ-
ences in the PK–PD parameter values and estimation error in
the pharmacodynamic parameters, with an actual patient. These
mismatches yield bias and fluctuation of the BIS if the model is
utilized in an open-loop controller. The closed-loop system can
attenuate the effects of these mismatches. However, more accu-
rate model improves the tracking ability and robust stability of
the closed-loop control system. A possible candidate is a com-
bined PK–PD model [26], whose plasma effect-site equilibra-
tion rate constant was derived in a more rigorous way.
B. Comparison With Manual Adjustment
As described in Section IV-C, the control system can main-
tain the BIS accurately and reduce the amount of propofol when
compared to manual adjustments. These results are attributable
to the accurate and adequate consideration of individual differ-
ences, the effect of time delays, and complex pharmacokinetics
of propofol. However, some future directions of our control
system are suggested by comparison with manual adjustments.
Before clinical trials, we anticipated that strict control of the
BIS would decrease the propofol consumption and facilitate
faster recovery from anesthesia. The averaged infusion rate is
decreased as expected. However, the recovery profiles are al-
most identical to those of the manual adjustment cases, as shown
in Table III.
A main reason for this lack of difference is the lack of consid-
eration for the progress of the surgery. In the cases of manual
adjustment, an anesthesiologist carefully monitors the patient
state and the progress of the surgery. For example, the infusion
rate would not be increased in the last stage of the surgery, even
if a sudden rise of the BIS were to occur from the pain of skin
sutures. On the other hand, our system only monitored the BIS,
noninvasive systolic pressure, and pulse rate, and was unable
to collect or use information about the progress of the surgery.
In each clinical trial, the instructions to the controller given by
the anesthesiologist were only two: “start infusion” and “stop
infusion.” Moreover, the target value, the control law, and the
risk control rules during the control period were the same for
all cases. Therefore, when a sudden BIS increase occurred be-
cause of skin sutures in the last stage of the surgery, the con-
troller administered a bolus of propofol until the BIS fell to 60.
This BIS fall might have caused a delay of awakening. Changing
the target point and risk control rules according to instructions
about the progress of the surgery might bring about less drug
consumption and earlier awakening.
VI. CONCLUSION
In this study, a hypnosis control system was developed using
a model-predictive controller. The system uses the BIS as the
index of hypnosis and propofol as an anesthetic drug. It has a
parameter estimation function of individual differences, in ad-
dition to a risk-control function. Results of clinical trials show
the potential of our system in reducing the amount of propofol
infusion and maintaining the BIS more accurately.
To improve the system effectiveness, we must consider the
following topics:
• developing a more accurate model;
• improving a more reliable method for parameter
estimation;
• optimizing rules for the risk control function.
APPENDIX
DERIVATION OF (12)
Subtracting each side of (8) from and multiplying them
by , we obtain
(24)
where BIS . Transposing some terms, we get
(25)
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